	US 11,738,040 B2
	Composition for treating joint disease and kit containing same
Kazuyuki Kano, Tokyo (JP); Yuji Nobuoka, Tokyo (JP); and Takayuki Seo, Tokyo (JP)
Assigned to SEIKAGAKU CORPORATION, Tokyo (JP)
Filed by SEIKAGAKU CORPORATION, Tokyo (JP)
Filed on Dec. 13, 2021, as Appl. No. 17/549,136.
Application 17/549,136 is a continuation of application No. 17/026,910, filed on Sep. 21, 2020, granted, now 11,229,666.
Application 17/026,910 is a continuation of application No. 16/493,934, granted, now 10,835,554, issued on Nov. 17, 2020, previously published as PCT/JP2018/009944, filed on Mar. 14, 2018.
Claims priority of application No. 2017-049203 (JP), filed on Mar. 14, 2017; and application No. 2017-132509 (JP), filed on Jul. 6, 2017.
Prior Publication US 2022/0096532 A1, Mar. 31, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/728 (2006.01); A61P 19/02 (2006.01); A61K 9/00 (2006.01); A61K 31/196 (2006.01)

CPC A61K 31/728 (2013.01) [A61K 9/0019 (2013.01); A61K 31/196 (2013.01); A61P 19/02 (2018.01)]

4 Claims

1. A method for treatment of a human joint disease, comprising:

administering at least three times with a composition containing a modified hyaluronic acid or a pharmaceutically acceptable salt thereof having a group of an anti-inflammatory compound as a sole active ingredient to a joint of a joint disease patient,

wherein the administration is performed every four weeks or more weeks,

wherein the composition is suitable for injection,

wherein the anti-inflammatory compound is diclofenac or a pharmaceutically acceptable salt thereof,

wherein 30 mg of the modified hyaluronic acid or a pharmaceutically acceptable salt thereof is administered in a single administration,

wherein an amount of the anti-inflammatory compound administered in a single administration is more than 1 mg and not more than 5 mg,

wherein the composition is an aqueous composition containing an aqueous solvent, and not less than 2 mL and not more than 4 mL of the aqueous composition is administered in a single administration,

wherein the treatment consists of improving and/or suppressing a symptom,

wherein the modified hyaluronic acid has a structure in which the group of an anti-inflammatory compound is covalently bonded to a hyaluronic acid base skeleton via a spacer of the following Formula (1):

—NR¹−R²—O— (1)

in Formula (1), R¹is a hydrogen atom; and R²is an ethylene group,

wherein the hyaluronic acid base skeleton consists of disaccharide units in which N-acetyl-D-glucosamine is linked to D-glucuronic acid by β-(1,3) bond are linked to each other by β-(1,4) bond,

wherein the hyaluronic acid base skeleton and the spacer is bonded by amide,

wherein the spacer and the group of an anti-inflammatory compound is bonded by ester,

wherein the joint disease is osteoarthritis, and

wherein the composition further comprises a pharmaceutically acceptable carrier.